Eiken Chemical’s financial results for the first quarter of fiscal year 2027 show net sales of approximately 10,728 million yen, a 5.2% increase YoY. Despite a 21.3% decrease YoY in operating profit to approximately 640 million yen, the company continues to contribute to medical fields through expanded sales of medical devices and test kits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4549","jir_company_name":"Eiken Chemical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4549-20260730-03.pdf","jir_short_summary":"Eiken Chemical's financial results for the first quarter of fiscal year 2027 show net sales of approximately 10,728 million yen, a 5.2% increase YoY. Despite a 21.3% decrease YoY in operating profit to approximately 640 million yen, the company continues to contribute to medical fields through expanded sales of medical devices and test kits.","jir_summary":"### Future Outlook and Impact on Investors\nThe company plans to continue strengthening sales of test kits and medical devices in response to the expanding demand in the healthcare sector. Through investments in research and development and the launch of new products, it aims for long-term growth. Investors should pay attention to contributions to medical fields, cost management, and the development of new markets.","jir_financial_highlights":"Net Sales: 10,728 million yen (Up 5.2% YoY)\nOperating Profit: 640 million yen (Down 21.3% YoY)\nNet Income: 445 million yen (Down 25.8% YoY)","jir_category":"","jir_hashtags":"#EikenChemicals, #FinancialResults, #JapanStocks","jir_key_figures":"Net Sales: 10,728 million yen (Up 5.2% YoY)\nOperating Profit: 640 million yen (Down 21.3% YoY)\nNet Income: 445 million yen (Down 25.8% YoY)","jir_meta_title":"\u3010Eiken Chemical\u3011First Quarter Financial Results\uff5cSales Increase but Profit Pressure, Future Outlook Focused","jir_meta_description":"Overview of Eiken Chemical's financial results for the first quarter of fiscal year 2027. Sales increased but profits declined. Detailed growth strategies and investment points.","jir_og_title":"\u3010Eiken Chemical\u3011First Quarter Financial Results\uff5cPoints on Sales Increase and Profit Pressure","jir_og_description":"Summary of Eiken Chemical's financial results and future outlook. Focus on expansion in medical fields and cost management.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q1\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Net Sales\\\", \\\"data\\\": [10197, 10728], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q1\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Profit\\\", \\\"data\\\": [800, 640], \\\"borderColor\\\": \\\"#FF6384\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2026 Q1\\\", \\\"2027 Q1\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Net Income\\\", \\\"data\\\": [600, 445], \\\"borderColor\\\": \\\"#4BC0C0\\\", \\\"fill\\\": false}]} \"}]","ir_related_company":16754,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90545","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n